Emergent BioSolutions to Participate in June 2010 Investor Conferences

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be participating in the following investor conferences during June 2010.

  • The Jefferies & Company 2010 Global Life Sciences Conference
    New York, NY.
    June 8, 2010
    Corporate Overview Presentation
    11:00 AM Eastern
    There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.
  • The Needham & Company 9th Annual Healthcare Conference
    New York, NY.
    June 10, 2010
    Corporate Overview Presentation
    3:20 PM Eastern
    There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.

Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.



CONTACT:

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
[email protected]
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical  Professional Services  Finance  Research  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.